CCL3 and neoplasm: CCL3/4 were reported to facilitate the infiltrating of inhibitive CCR5+ MDSCs, and concurrent blocking CCR5/CCR5‐ligand and PD1/PD‐L1 axes could enhance efficacy and prolong survival in preclinical tumor models.46